The updates and recommendations by the CDC and several organizations include the addition of the COVID-19 vaccine for pediatric patients and a new pneumococcal conjugate vaccine.
The Advisory Committee on Immunization Practices has released its updates to the annual immunization schedules for 2023 that includes new sections on COVID-19 and polio vaccine recommendations.
The Centers for Disease Control and Prevention (CDC) have released updated recommendations regarding the use of 13-valent pneumococcal conjugate vaccine (PCV13) and 23-valent pneumococcal polysaccharide...
When PCV7 was introduced in pediatric immunization programs, adults experienced a significant decrease in pneumococcal disease. A new study evaluated the more recent introduction of the PCV13 and its impact...
The PPSV23—a long-standing, safe pneumococcal vaccine—and the newer PCV13 have both been recommended for adults aged 65 years and older. In a new study, researchers aimed to compare the safety profiles of...
The 13-valent pneumococcal conjugate vaccine (PCV13) was first introduced in the United States in 2010. However, the effect of PCV13 on pneumococcal meningitis is not currently known.
While children undergoing immunosuppressive treatment for cancer are known to have a high risk for invasive pneumococcal disease, few studies have examined the safety and efficacy of the PCV13 in this...
